| Symbol | ANNX |
|---|---|
| Name | ANNEXON, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1400 SIERRA POINT PARKWAY, BLDG C,SUITE 200, BRISBANE, California, 94005, United States |
| Telephone | +1 650 822-5500 |
| Fax | — |
| — | |
| Website | https://www.annexonbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001528115 |
| Description | Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexons product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases. Additional info from NASDAQ: |
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Read more📋 WIGGANS THOMAS G (Ex-Director) plans to sell 2K shares of Annexon, Inc. (at $5.30 each, total $11K) Filed: Aug 13, 2026 | ID: 005993
Read moreNew Form 3 - Annexon, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001614869-26-000003 <b>Size:</b> 11 KB
Read moreAnnexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Read moreAnnexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
Read moreNew Form SCHEDULE 13G - Annexon, Inc. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000411 <b>Size:</b> 8 KB
Read moreAnnexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07807969 | An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) i… | Phase3 | Geographic Atrophy | Not_Yet_Recruiting | 2026-09-30 | 2029-07-31 | ClinicalTrials.gov |
| NCT07020819 | An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as A… | Phase3 | Guillain-Barre Syndrome | Recruiting | 2025-09-12 | 2028-06-30 | ClinicalTrials.gov |
| NCT06510816 | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections … | Phase3 | Geographic Atrophy | Active_Not_Recruiting | 2024-07-30 | 2027-07-31 | ClinicalTrials.gov |
| NCT05780515 | A Study of ANX009 in Adult Participants With Lupus Nephritis | Phase1 | Lupus Nephritis | Completed | 2022-08-09 | 2023-10-31 | ClinicalTrials.gov |
| NCT05521269 | Dose Study of ANX1502 in Healthy Volunteers | Phase1 | Healthy | Completed | 2022-06-27 | 2024-11-19 | ClinicalTrials.gov |
| NCT05288881 | Single Ascending Dose Study of ANX105 | Phase1 | Healthy | Completed | 2022-02-28 | 2023-06-19 | ClinicalTrials.gov |
| NCT04691570 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Partic… | Phase2 | Warm Autoimmune Hemolytic Anemia (wAIHA) | Completed | 2021-11-10 | 2023-01-17 | ClinicalTrials.gov |
| NCT04656561 | A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX… | Phase2 | Geographic Atrophy | Completed | 2021-02-26 | 2023-09-13 | ClinicalTrials.gov |
| NCT04569435 | Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2021-01-15 | 2024-04-23 | ClinicalTrials.gov |
| NCT04701164 | Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome | Phase3 | Guillain-Barre Syndrome | Completed | 2020-12-17 | 2024-04-20 | ClinicalTrials.gov |
| NCT04535752 | A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Voluntee… | Phase1 | Safety and Tolerability in Healthy Volunteers | Completed | 2020-10-30 | 2021-06-26 | ClinicalTrials.gov |
| NCT04514367 | An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Hu… | Phase2 | Huntington Disease | Completed | 2020-09-29 | 2022-08-29 | ClinicalTrials.gov |
| NCT04035135 | A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (G… | Phase1 | Guillain-Barré Syndrome | Completed | 2020-01-29 | 2021-05-19 | ClinicalTrials.gov |
| NCT04188015 | Study of ANX007 in Participants With Primary Open-angle Glaucoma | Phase1 | Open Angle Glaucoma | Completed | 2018-07-25 | 2019-06-03 | ClinicalTrials.gov |
| NCT03488550 | Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma | Phase1 | Open-angle Glaucoma | Completed | 2018-03-23 | 2018-08-03 | ClinicalTrials.gov |
| NCT03010046 | Single Dose Study of ANX005 in Healthy Volunteers | Phase1 | Safety and Tolerability in Healthy Volunteers | Terminated | 2016-12-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT07424235 | Evaluating the Relationship Between Function and Structure in ARCHER II-like Po… | — | Age Related Macular Degeneration (AMD) | Completed | 2015-01-01 | 2024-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | NOT_YET_RECRUITING | NCT07807969 |
| ANX005 | Other | Phase PHASE2 | Huntington Disease | COMPLETED | NCT04514367 |
| ANX005 | Other | Phase PHASE2 | Warm Autoimmune Hemolytic Anemia (wAIHA) | COMPLETED | NCT04691570 |
| Tanruprubart | Other | Phase PHASE3 | Guillain-Barre Syndrome | RECRUITING | NCT07020819 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Procedure | Procedure | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| 5.0mg ANX007 | Other | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| 2.5mg ANX007 | Other | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| ANX007 | Other | Phase PHASE1 | Open-angle Glaucoma | COMPLETED | NCT03488550 |
| Placebos | Other | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | TERMINATED | NCT03010046 |
| IVIg | Other | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | TERMINATED | NCT03010046 |
| ANX005 | Other | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | TERMINATED | NCT03010046 |
| Intravenous immunoglobulin | Other | Phase PHASE1 | Guillain-Barré Syndrome | COMPLETED | NCT04035135 |
| ANX005 | Other | Phase PHASE1 | Guillain-Barré Syndrome | COMPLETED | NCT04035135 |
| Placebo | Other | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | COMPLETED | NCT04535752 |
| ANX009 | Other | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | COMPLETED | NCT04535752 |
| ANX005 | Other | Phase PHASE2 | Huntington Disease | COMPLETED | NCT04514367 |
| ANX005 | Other | Phase PHASE2 | Warm Autoimmune Hemolytic Anemia (wAIHA) | COMPLETED | NCT04691570 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05288881 |
| ANX105 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05288881 |
| Sham comparator | Other | Phase PHASE2 | Geographic Atrophy | COMPLETED | NCT04656561 |
| ANX007 | Other | Phase PHASE2 | Geographic Atrophy | COMPLETED | NCT04656561 |
| ANX009 | Other | Phase PHASE1 | Lupus Nephritis | COMPLETED | NCT05780515 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05521269 |
| ANX1502 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05521269 |
| ANX005 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT04569435 |
| Placebo | Other | Phase PHASE3 | Guillain-Barre Syndrome | COMPLETED | NCT04701164 |
| ANX005 | Other | Phase PHASE3 | Guillain-Barre Syndrome | COMPLETED | NCT04701164 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Tanruprubart | Other | Phase PHASE3 | Guillain-Barre Syndrome | RECRUITING | NCT07020819 |
| Tanruprubart | DRUG | Phase PHASE3 | Guillain-Barre Syndrome | RECRUITING | NCT07020819 |
| Sham Administration | OTHER | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | DRUG | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| ANX1502 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05521269 |
| ANX105 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT05288881 |
| Sham comparator | OTHER | Phase PHASE2 | Geographic Atrophy | COMPLETED | NCT04656561 |
| Placebo | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05521269 |
| ANX009 | BIOLOGICAL | Phase PHASE1 | Lupus Nephritis | COMPLETED | NCT05780515 |
| Sham Procedure | OTHER | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| 5.0mg ANX007 | BIOLOGICAL | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| 2.5mg ANX007 | BIOLOGICAL | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| Intravenous immunoglobulin | DRUG | Phase PHASE1 | Guillain-Barré Syndrome | COMPLETED | NCT04035135 |
| ANX007 | DRUG | Phase PHASE2 | Geographic Atrophy | COMPLETED | NCT04656561 |
| Placebos | DRUG | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | TERMINATED | NCT03010046 |
| IVIg | DRUG | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | TERMINATED | NCT03010046 |
| ANX005 | DRUG | Phase PHASE3 | Guillain-Barre Syndrome | COMPLETED | NCT04701164 |